Nektar lifted by Merck alliance for bempeg, new trial funding
Pharma Phorum
FEBRUARY 18, 2021
Merck will pair Keytruda (pembrolizumab) with bempegaldesleukin (NKTR-214) – known as bempeg for short – in a phase 2/3 trial involving patients with squamous cell carcinoma of the head and neck (SCCHN) that if positive could support regulatory filings.
Let's personalize your content